---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-010485"
form_type: "8-K"
ticker: "VSTM"
cik: "0001526119"
company_name: "Verastem, Inc."
filed_at: "2023-05-25T23:59:59+00:00"
generated_at: "2026-06-14T14:28:38.502907+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Verastem reports 45% ORR for avutometinib+defactinib in RAMP 201 LGSOC trial

## Summary
- Combination achieved 45% ORR (13/29 evaluable) and tumor shrinkage in 86% of heavily pretreated LGSOC patients.
- KRAS mutant subgroup ORR 60% (9/15); KRAS wild type ORR 29% (4/14); median response time 5.5 months.
- Safety profile consistent with prior data; discontinuation rate 12%, mostly due to elevated CPK (4.9%).
- FDA Breakthrough Therapy Designation previously granted; company plans filing for accelerated approval.

## SEC filing metadata
- accession: 0001558370-23-010485
- form_type: 8-K
- ticker: VSTM
- cik: 0001526119
- company_name: Verastem, Inc.
- filed_at: 2023-05-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1526119/000155837023010485/0001558370-23-010485-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1526119/000155837023010485/vstm-20230525x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-010485
- JSON: https://secwatch.observer/filing/0001558370-23-010485.json
- Plain text: https://secwatch.observer/filing/0001558370-23-010485.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.